Namodenoson not checked

Can-Fite BioPharma · CF102

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
2 active
5 in total · 1 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Hepatocellular Carcinoma, Cirrhosis, Pancreatic Adenocarcinoma, Pancreatic Cancer
Main trialPhase 3
“This is a clinical trial in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh Class B7 (CPB7) cirrhosis whose disease has progressed on at least 1st-line therapy. The trial will evaluate the efficacy and safety of namodenoson as compared to placebo.”In the company’s words, NCT05201404 on ClinicalTrials.gov
Other names
CF102 · IB-MECA · Cl-IB-MECA

Other drugs for Hepatocellular Carcinoma

All 130 drugs for Hepatocellular Carcinoma

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Feb 2026 Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
Phase 2Recruiting 15 Jul 2026 Namodenoson Treatment of Advanced Pancreatic Cancer
Phase 2Completed 27 Nov 2017 Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)
Phase 2Unknown 15 Apr 2025 Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Phase 1/2Completed Dec 2012 A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Namodenoson

Following is part of Solo: you see every change to Namodenoson the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in